Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Mark de Serres"'
Autor:
James Myer, J. Sigafoos, David S. Wagner, Mark de Serres, M. Reid Groseclose, Joseph W. Polli, Stephen Castellino, Elizabeth Romach, Brad Hamilton
Publikováno v:
Chemical Research in Toxicology. 26:241-251
The CNS disposition and metabolism of Fosdevirine (FDV), an HIV non-nucleoside reverse transcriptase inhibitor, was investigated in four patients who unexpectedly experienced seizures after at least 4 weeks of treatment in a Phase IIb, HIV-1 treatmen
Autor:
Steve Piscitelli, Mark Johnson, Xiao-Jian Zhou, J. Kim, Elizabeth Gould, Keith Pietropaolo, Scott White, Douglas L. Mayers, Yu Lou, Mark de Serres
Publikováno v:
British Journal of Clinical Pharmacology. 74:336-345
AIM To evaluate potential drug interactions with antiretroviral therapies or supportive therapies for use in conjunction with the once daily, next generation non-nucleoside reverse transcriptase inhibitor GSK2248761 in patients with HIV-1 infection.
Publikováno v:
Drug Metabolism Letters. 4:180-184
Morphological evaluation of humanized chimeric mouse livers from the PhoenixBio (uPA(+/+)/SCID) mouse model show robust replacement and expansion with human hepatocytes, however areas of human hepatocytes had prominent steatosis and a variable lack o
Autor:
Lee Moss, Cosette J. Serabjit-Singh, Andrea M. Sefler, J. Sigafoos, Mark de Serres, Stephen Castellino, Gary D Bowers
Publikováno v:
Xenobiotica. 40:437-445
GW695634 is the prodrug of GW678248, a novel non-nucleoside reverse transcriptase inhibitor with potent antiviral activity against HIV/AIDS efavirenz- and nevirapine-resistant viruses. In mice, rats, and monkeys following oral administration of [(14)
Autor:
Byron Ellis, Debra Weigl, Jeff T. Hutchins, Mark de Serres, Randolph B. DePrince, John E. Dillberger, Sharon K. Rudolph, Christine M. Boytos
Publikováno v:
STEM CELLS. 17:203-209
Administration of exogenous proteins and peptides as therapeutics carries with it the potential for immune system recognition and the development of neutralizing antibodies to endogenous regulatory proteins. PEGylation of proteins typically reduces t
Autor:
David S. Wagner, Vishal Shah, J. Sigafoos, Russell L. Yeager, Steve Castellino, Gary D Bowers, Gary Boyle, Mark de Serres, Andrew D. Roberts, Mehul Dave, Claire Beaumont, Katie L Olson, Cosette J. Serabjit-Singh, Dipak K. Patel
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 41(6)
A model that predicts human metabolism and disposition of drug candidates would be of value in early drug development. In this study, a chimeric (uPA+/+)/SCID mouse model was evaluated with three structurally distinct compounds (GW695634, a benzophen
Publikováno v:
Drug metabolism letters. 1(2)
Fresh hepatocytes have been the choice for interspecies comparative drug metabolism studies. Cryopreserved hepatocytes represent a readily available alternative when combined with acceptance limits based on the metabolic turnover of 7-ethoxycoumarin.
Autor:
Beth Case, John E. Dillberger, Mark de Serres, Marlene L. Hauck, Anita H. Simkins, Russell L. Yeager, Virginia D. Schmith, Rodney L. Page
Publikováno v:
Stem cells (Dayton, Ohio). 18(5)
GW395058, a PEGylated peptide agonist of the thrombopoietin receptor, stimulates megakaryocytopoiesis and has previously been shown to increase platelet counts in vivo. The pharmacokinetics and pharmacodynamics of GW395058 were characterized using a
Autor:
Mark de Serres, John E. Dillberger, Jeffry M. Sailstad, M. J. Mcnulty, Anita H. Simkins, Guy H. Gardner, Cathleen A. Rubens, Guy Lalonde, Joseph L. Woolley, Russ L. Yeager
Publikováno v:
Stem cells (Dayton, Ohio). 17(6)
GW395058, a potent PEGylated peptide human thrombopoietin receptor (HuTPOr) agonist in vitro, is being evaluated for the treatment of thrombocytopenia. GW395058 shares no sequence homology with TPO. In this report the pharmacokinetics and hematologic
Publikováno v:
Analytical biochemistry. 233(2)
A novel scintillation proximity competitive hybridization assay was developed for determining plasma concentrations of compound 4003W94, a 15-base phosphorothioate antisense deoxyribonucleotide that is currently under preclinical evaluation for the t